dapagliflozin - NICE guidance for treating chronic heart failure with reduced ejection fraction

Last edited 03/2021 and last reviewed 06/2023

Dapagliflozin is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction in adults, only if it is used as an add-on to optimised standard care with:

• angiotensin-converting enzyme (ACE) inhibitors or angiotensin-2 receptor blockers (ARBs), with beta blockers, and, if tolerated, mineralocorticoid receptor antagonists (MRAs), or
• sacubitril valsartan, with beta blockers, and, if tolerated, MRAs

Start treatment of symptomatic heart failure with reduced ejection fraction with dapagliflozin on the advice of a heart failure specialist. Monitoring should be done by the most appropriate healthcare professional.

Reference:

1. NICE (February 2021). Dapagliflozin for treating chronic heart failure with reduced ejection fraction